AI Drug Discovery Specialised for Cardiovascular Disease   

PngItem_672961.png
 
Screenshot 2021-10-14 at 13.51.56.png

Knowledge Integration 
 
AI driven collation and analysis of highly fragmented datasets to form the industry's most representative and holistic cardiovascular metabolic pathway maps

Screenshot 2021-10-14 at 11.32.27.png
Screenshot 2021-10-14 at 11.33.26.png
Screenshot 2021-10-14 at 11.32.04.png

Database Development 

Data integrated into CardiaTec's proprietary Cardiosome* database, for targeted analysis and integrated pathway modelling

Screenshot 2021-10-14 at 11.33.26.png

Drug Discovery 

Leveraging AI for target identification and novel drug discovery to deliver the next generation of therapeutics for cardiovascular diseases

Screenshot 2021-10-14 at 12.02.35.png
thisisengineering-raeng-prFWu21zgqg-unsplash.jpg

Precision Medicine

Transforming current one-size-fits-all approaches to personalised and effective medical intervention 

 

TEAM

rphnN8ig.jpg

Namshik Han


Co-founder, CTO


Head of Artificial Intelligence at Milner Therapeutics Institute, Associate Faculty at Cambridge Centre for AI in Medicine, University of Cambridge.
 

YCC � ABC_8707 (1) (1).jpg

Raphael Peralta

 

Co-founder, CEO


BSc Biology, MSc Biotechnology & MPhil Bioscience Enterprise, University of Cambridge, with previous experience in life science project managment & Consulting. 

1601299071685.jpg

Thelma Zablocki 

 

Co-founder, COO


BSc Bioengineering & MPhil Bioscience Enterprise, University of Cambridge, with previous experience in life science VC & Consulting. 

 

Get in touch 

Contact us for more information on our approach, collaborations and for joining us on a unique venture: 

        Rperalta@cardiatec.co.uk  

nodeGarden5000.jpg